文献速递呼吸道感染

JAK抑制剂对住院COVID-19成人患者的疗效:随机临床试验的系统综述与个体参与者数据Meta分析

Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials.
PubMed 文献 · Lancet Respir Med · 2025-05-13

高质量证据),减少有创机械通气或呼吸支持需求并加快出院约1天,且3-4级不良事件和严重不良事件更少。

要点

  • JAK抑制剂降低住院COVID-19成人28天全因死亡率,每1000例减少39例死亡。
  • JAK抑制剂减少新需要有创机械通气或其他呼吸支持,并加快出院约1天。
  • JAK抑制剂组3-4级不良事件和严重不良事件更少,特殊关注不良事件两组相似。

核心结论

  • JAK抑制剂可降低住院COVID-19成人28天全因死亡率,且在不同呼吸支持水平、是否联用地塞米松或托珠单抗情况下均一致。
  • JAK抑制剂可能减少严重和3-4级不良事件,特殊关注不良事件发生率与对照组相似。

研究设计与样本

  • 系统综述与个体参与者数据Meta分析(IPDMA),检索Medline、Embase、Cochrane CENTRAL、Cochrane COVID-19 Study Register及COVID-19 L·OVE Platform,末次检索2024年11月28日。
  • 主要结局为随机分配后28天全因死亡率,采用两阶段Meta分析调整年龄和呼吸支持,随机效应模型合并估计值。

主要发现

  • JAK抑制剂减少新需要有创机械通气或其他呼吸支持的需求,并使出院时间加快约1天。
  • JAK抑制剂组3-4级不良事件和严重不良事件更少(每1000例减少14例,95%CI 减少24至减少4),中等质量证据;特殊关注不良事件两组相似。
  • 未发现呼吸支持状态、JAK抑制剂类型、合并症、症状出现后治疗启动时机、C反应蛋白浓度或联用地塞米松/托珠单抗对28天死亡率有可信的亚组效应。
  • 年龄存在中等可信度的效应修饰,年轻参与者相对治疗效应更大,但因老年参与者基线风险更高,绝对治疗效应相似。

关键数值与推荐

  • 3-4级不良事件和严重不良事件:每1000例减少14例(95%CI 减少24至减少4),中等质量证据。
  • 亚组分析未发现呼吸支持状态、JAK抑制剂类型、合并症、治疗时机、CRP或联用地塞米松/托珠单抗对28天死亡率有可信效应修饰。
  • 年龄对28天死亡率存在中等可信度效应修饰,年轻参与者相对效应更大,绝对效应相似。

临床怎么用

  • 对于住院COVID-19成人患者,JAK抑制剂可考虑用于降低28天死亡风险,且不受呼吸支持水平或是否联用地塞米松/托珠单抗影响。
  • JAK抑制剂可能减少严重不良事件,并加快出院约1天,有助于缩短住院时间。
  • 年轻患者相对获益更大,但老年患者因基线风险高,绝对获益相似,临床决策需结合个体风险评估。

局限性

  • 仅从16项合格试验中的12项获得个体参与者数据,未覆盖全部合格试验。
  • 纳入试验集中于2020年5月至2022年3月入组,可能不完全反映后续病毒变异和诊疗变化。
  • 年龄对治疗效应的修饰为中等可信度,其他亚组分析未发现可信效应修饰。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence from randomised clinical trials (RCTs) of Janus kinase (JAK) inhibitors-compared with usual care or placebo-in adults treated in hospital for COVID-19 is conflicting. We aimed to evaluate the benefits and harms of JAK inhibitors compared with placebo or usual care and whether treatment effects differed between prespecified participant subgroups. METHODS: For this systematic review and individual participant data meta-analysis (IPDMA), we searched Medline via Ovid, Embase via Elsevier, the Cochrane Central Register of Controlled Trials, the Cochrane COVID-19 Study Register, and the COVID-19 L·OVE Platform, including backward and forward citation searching (last search Nov 28, 2024), for RCTs (unpublished or published in any format and any language) that randomly assigned adults (aged ≥16 years) admitted to a hospital due to COVID-19 to receive either a JAK inhibitor (any type) or no JAK inhibitor (ie, received site-specific standard of care with or without placebo), and requested individual participant data (IPD) from the original trial teams. The primary outcome was all-cause mortality at day 28 after random assignment. We used two-stage meta-analyses adjusting for age and respiratory support, and pooled estimates using random-effects models. The assessment of individual-level effect modifiers was based solely on within-trial information and continuous modifiers were investigated as both linear and non-linear interactions. We used the Instrument for Assessing the Credibility of Effect Modification Analyses to appraise the subgroup analyses and the Grading of Recommendations Assessment, Development, and Evaluation approach to adjudicate the certainty of evidence. Grade 3 or 4 adverse events and serious adverse events by day 28, and adverse events of special interest within 28 days, were assessed among secondary outcomes. This study was registered with PROSPERO (CRD42023431817). FINDINGS: We identified 16 eligible trials. IPD were obtained from 12 trials, corresponding to 12 902 adults admitted to hospital between May, 2020, and March, 2022. These trials represented 12 902 [96·1%] of 13 423 participants from all eligible trials worldwide. Seven trials evaluated baricitinib, three evaluated tofacitinib, and two evaluated ruxolitinib. Overall, 755 (11·7%) of 6465 participants in the JAK inhibitor group died by day 28 compared with 805 (13·2%) of 6108 participants in the no JAK inhibitor group (adjusted odds ratio [aOR] 0·67 [95% CI 0·55-0·82]; high-certainty evidence; 39 fewer per 1000 [95% CI 55 fewer to 21 fewer]). JAK inhibitors decreased the need for new mechanical ventilation or other respiratory support and allowed for faster discharge from hospital by about 1 day. We observed fewer grade 3 and 4 adverse events and serious adverse events in the JAK inhibitor group (14 fewer per 1000 [95% CI 24 fewer to 4 fewer]; moderate-certainty evidence). The rates of adverse events of special interest were similar across both groups. No credible subgroup effect on mortality at day 28 was found for ventilation status, type of JAK inhibitor, presence of comorbidities, timing of treatment initiation after symptom onset, C-reactive protein concentration, or concomitant use of dexamethasone or tocilizumab. We found a moderately credible effect modification by age, with younger participants showing larger relative treatment effects than older participants, but similar absolute treatment effects due to higher baseline risk for older participants. INTERPRETATION: This IPDMA of RCTs in adults admitted to hospital due to COVID-19 found that JAK inhibitors reduced mortality across all levels of respiratory support, independent of dexamethasone or tocilizumab, and probably decreased serious and severe adverse events compared with no JAK inhibitors. FUNDING: This project has received funding from the EU's Horizon 2020 research and innovation programme under grant agreement number 101015736.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Amstutz A, Schandelmaier S, Ewald H, et al. Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials. Lancet Respir Med. 2025. PMID: 40378861. doi:10.1016/S2213-2600(25)00055-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。